Top 10 States With Most Millionaires Per Person: 2018
Clients Rate Top Financial Services Firms in 13 Categories
7 Facts About Trumps 2019 Budget Proposal, for Agents
LPL Financial shared a list of advisors and teams that choose to affiliate with its platform in the final three months of 2017 on Thursday. These recruiting efforts resulted in a total of 125 advisors with at least $2.9 billion and as much as $6.1 billion in total client assets moving to the independent broker-dealer in the fourth quarter.
In the category of advisors and teams with over $100 million in assets, a group of 23 advisors previously affiliated with Cetera Investment Services switched to LPL, as did a team of 11 reps working earlier with Invest Financial.
Another 13 advisors and teams moved to LPL in this asset category from Cetera Advisor Networks, Edward Jones, Wells Fargo and other firms. The total asset level these 47 advisors could bring to LPL is at least $1 billion.
Best Financial Stocks To Watch For 2018: Exa Corporation(EXA)
- [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
- [By Monica Gerson]
Exa Corp (NASDAQ: EXA) is projected to post a quarterly loss at $0.08 per share on revenue of $16.68 million.
Thermon Group Holdings Inc (NYSE: THR) is estimated to report its quarterly earnings at $0.19 per share on revenue of $65.24 million.
Best Financial Stocks To Watch For 2018: Novellus Systems Inc.(NVLS)
- [By Chris Lange]
Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.
- [By Paul Ausick]
Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.
- [By Lisa Levin]
Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.
Best Financial Stocks To Watch For 2018: Layne Christensen Company(LAYN)
- [By Lisa Levin]
Shares of Layne Christensen Company (NASDAQ: LAYN) got a boost, shooting up 16 percent to $8.78 after the company posted a narrower-than-expected loss for its first quarter.
- [By Peter Graham]
A long term performance chart shows small caps Great Lakes Dredge & Dock Corporation andLayne Christensen Company (NASDAQ: LAYN) underperforming, but possibly recovering while Orion Group Holdings (NYSE: ORN) had a clear reversal early last year: